153 related articles for article (PubMed ID: 28509618)
1. Follow-up of patients with thyroglobulin-antibodies: Rising Tg-Ab trend is a risk factor for recurrence of differentiated thyroid cancer.
de Meer SGA; Vorselaars WMCM; Kist JW; Stokkel MPM; de Keizer B; Valk GD; Borel Rinkes IHM; Vriens MR
Endocr Res; 2017 Nov; 42(4):302-310. PubMed ID: 28509618
[TBL] [Abstract][Full Text] [Related]
2. Prevalence, clinical significance and prognostic value of anti-thyroglobulin antibodies in the follow-up of patients with differentiated thyroid carcinoma: a retrospective study.
Pedrazzini L; Baroli A; Lomuscio G; Marzoli L
Minerva Endocrinol; 2009 Sep; 34(3):195-203. PubMed ID: 19859043
[TBL] [Abstract][Full Text] [Related]
3. Serum thyroglobulin in the monitoring of differentiated thyroid cancer.
Evans C; Tennant S; Perros P
Scand J Clin Lab Invest Suppl; 2016; 245():S119-23. PubMed ID: 27542000
[TBL] [Abstract][Full Text] [Related]
4. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.
Kim TY; Kim WB; Kim ES; Ryu JS; Yeo JS; Kim SC; Hong SJ; Shong YK
J Clin Endocrinol Metab; 2005 Mar; 90(3):1440-5. PubMed ID: 15613412
[TBL] [Abstract][Full Text] [Related]
5. On-levothyroxine measurement of thyroglobulin is not a reliable test for the follow-up of patients at high risk for remnant/recurrent differentiated thyroid carcinoma.
Gholamrezanezhad A; Saghari M; Mirpour S; Beiki D; Tarbiat A; Javan S; Abdollahzadeh J
Endokrynol Pol; 2007; 58(2):100-4. PubMed ID: 17578824
[TBL] [Abstract][Full Text] [Related]
6. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
[TBL] [Abstract][Full Text] [Related]
7. Thyroglobulin - what is the postoperative threshold for the suspicion of thyroid cancer recurrence in the absence of anti-Tg antibody measurement?
Papageorgiou MS; Liratzopoulos N; Minopoulos G; Manolas KJ
S Afr J Surg; 2011 Aug; 49(3):118-22. PubMed ID: 21933495
[TBL] [Abstract][Full Text] [Related]
8. [Advances in thyroglobulin assays and their impact on the management of differentiated thyroid cancers].
d'Herbomez M; Lion G; Béron A; Wémeau JL; DoCao C
Ann Biol Clin (Paris); 2016; 74(1):21-7. PubMed ID: 26711165
[TBL] [Abstract][Full Text] [Related]
9. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level.
Asa S; Aksoy SY; Vatankulu B; Aliyev A; Uslu L; Ozhan M; Sager S; Halac M; Sonmezoglu K
Ann Nucl Med; 2014 Dec; 28(10):970-9. PubMed ID: 25120245
[TBL] [Abstract][Full Text] [Related]
10. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
[TBL] [Abstract][Full Text] [Related]
11. Thyroid cancer recurrence in patients clinically free of disease with undetectable or very low serum thyroglobulin values.
Kloos RT
J Clin Endocrinol Metab; 2010 Dec; 95(12):5241-8. PubMed ID: 20843945
[TBL] [Abstract][Full Text] [Related]
12. The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation.
Phan HT; Jager PL; van der Wal JE; Sluiter WJ; Plukker JT; Dierckx RA; Wolffenbuttel BH; Links TP
Eur J Endocrinol; 2008 Jan; 158(1):77-83. PubMed ID: 18166820
[TBL] [Abstract][Full Text] [Related]
13. [Recurrence of differentiated thyroid carcinoma without concomitant elevation of serum thyroglobulin: report of two cases].
Velasco S; Solar A; Cruz F; Quintana JC; León A; Mosso L; Fardella C
Rev Med Chil; 2007 Apr; 135(4):506-11. PubMed ID: 17554461
[TBL] [Abstract][Full Text] [Related]
14. Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma.
Giovanella L; Maffioli M; Ceriani L; De Palma D; Spriano G
Clin Chem Lab Med; 2009; 47(8):1001-4. PubMed ID: 19589104
[TBL] [Abstract][Full Text] [Related]
15. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma.
Ringel MD; Balducci-Silano PL; Anderson JS; Spencer CA; Silverman J; Sparling YH; Francis GL; Burman KD; Wartofsky L; Ladenson PW; Levine MA; Tuttle RM
J Clin Endocrinol Metab; 1999 Nov; 84(11):4037-42. PubMed ID: 10566646
[TBL] [Abstract][Full Text] [Related]
16. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement.
Spencer CA; LoPresti JS; Fatemi S; Nicoloff JT
Thyroid; 1999 May; 9(5):435-41. PubMed ID: 10365673
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients.
Brassard M; Borget I; Edet-Sanson A; Giraudet AL; Mundler O; Toubeau M; Bonichon F; Borson-Chazot F; Leenhardt L; Schvartz C; Dejax C; Brenot-Rossi I; Toubert ME; Torlontano M; Benhamou E; Schlumberger M;
J Clin Endocrinol Metab; 2011 May; 96(5):1352-9. PubMed ID: 21389143
[TBL] [Abstract][Full Text] [Related]
18. Ablative free thyroxine to thyroglobulin ratio as a predictor of differentiated thyroid cancer recurrence.
Aron M; Cote V; Tamilia M; Hier M; Black MJ; Zhang X; Payne RJ
J Otolaryngol Head Neck Surg; 2009 Oct; 38(5):552-8. PubMed ID: 19769825
[TBL] [Abstract][Full Text] [Related]
19. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients.
Schlumberger M; Hitzel A; Toubert ME; Corone C; Troalen F; Schlageter MH; Claustrat F; Koscielny S; Taieb D; Toubeau M; Bonichon F; Borson-Chazot F; Leenhardt L; Schvartz C; Dejax C; Brenot-Rossi I; Torlontano M; Tenenbaum F; Bardet S; Bussière F; Girard JJ; Morel O; Schneegans O; Schlienger JL; Prost A; So D; Archambeaud F; Ricard M; Benhamou E
J Clin Endocrinol Metab; 2007 Jul; 92(7):2487-95. PubMed ID: 17426102
[TBL] [Abstract][Full Text] [Related]
20. Post-ablative serum thyroglobulin is an independent predictor of recurrence in low-risk differentiated thyroid carcinoma: a 16-year follow-up study.
Pelttari H; Välimäki MJ; Löyttyniemi E; Schalin-Jäntti C
Eur J Endocrinol; 2010 Nov; 163(5):757-63. PubMed ID: 20813788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
